A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice

被引：0
作者：
Jovin J. Y. Choo
Laura J. Vet
Christopher L. D. McMillan
Jessica J. Harrison
Connor A. P. Scott
Alexandra C. I. Depelsenaire
Germain J. P. Fernando
Daniel Watterson
Roy A. Hall
Paul R. Young
Jody Hobson-Peters
David A. Muller
机构：
[1] The University of Queensland,Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences
[2] Translational Research Institute,Vaxxas Pty Ltd
来源：
npj Vaccines | / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development, with one having already been licensed, albeit with limited distribution. We investigated the immunogenicity and protective efficacy of a chimeric virus vaccine candidate based on the insect-specific flavivirus, Binjari virus (BinJV), displaying the structural prM/E proteins of DENV (BinJ/DENV2-prME). In this study, we immunized AG129 mice with BinJ/DENV2-prME via a needle-free, high-density microarray patch (HD-MAP) delivery system. Immunization with a single, 1 µg dose of BinJ/DENV2-prME delivered via the HD-MAPs resulted in enhanced kinetics of neutralizing antibody induction when compared to needle delivery and complete protection against mortality upon virus challenge in the AG129 DENV mouse model.
引用
收藏
相关论文
共 61 条
  • [1] Bhatt S(2013)The global distribution and burden of dengue Nature 496 504-507
  • [2] Guzman MG(2010)Dengue: a continuing global threat Nat. Rev. Microbiol. 8 S7-S16
  • [3] Wilder-Smith A(2019)Dengue Lancet 393 350-363
  • [4] Ooi E-E(2015)Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past Virol. Sin. 30 326-343
  • [5] Horstick O(2016)Association of microvascular function and endothelial biomarkers with clinical outcome in dengue: an observational study J. Infect. Dis. 214 697-706
  • [6] Wills B(2009)Dengue virus pathogenesis: an integrated view Clin. Microbiol. Rev. 22 564-581
  • [7] Islam R(2011)The human antibody response to dengue virus infection Viruses 3 2374-2395
  • [8] Yacoub S(2004)Dengue: defining protective versus pathologic immunity J. Clin. Invest. 113 946-951
  • [9] Martina BE(1977)Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody J. Exp. Med. 146 201-217
  • [10] Koraka P(2014)Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial Lancet 384 1358-1365
1234567